Pharmacogenetics in pain management: the clinical need.
Genetic research heralds a new therapeutic approach to pain management. Increasing literature demonstrates individual genetic vulnerabilities to specific pain types and mechanisms, partially explaining differing responses to similar pain stimuli. Furthermore, analgesics demonstrate great variability among polymorphic genotypes. Family history and genotyping promise to play an important role in future pain therapies. As advances continue in the genetics of pain and analgesia, pharmacotherapy will depend more on an individualized, targeted approach and less on empiricism.
Webster
Lynn R
LR
Lifetree Clinical Research and Pain Clinic, 3838 South, 700 East, Suite 200, Salt Lake City, UT 84106, USA. lynnw@lifetreepain.com
D000700:Analgesics / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D005838:Genotype; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000235:genetics; D010147:Pain Measurement; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D044102:Receptor, Melanocortin, Type 1 / Q000235:genetics; D017450:Receptors, Opioid, mu / Q000235:genetics
D000700:Analgesics; C485764:OPRM1 protein, human; D044102:Receptor, Melanocortin, Type 1; D017450:Receptors, Opioid, mu; D019389:Cytochrome P-450 CYP2D6; D002394:Catechol O-Methyltransferase